$SNEX

BEXIGA ANNABELLE G sold $200K of SNEX

BEXIGA ANNABELLE G sold 1,500 shares of StoneX Group Inc. (SNEX) at $133.36 ($0.20M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · BEXIGA ANNABELLE G
Published Jun 16, 2026, 8:31 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNEX
Neutral
high confidence
Mentioned
$SNEX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNEXNeutralLow
01

Why it matters

A director open-market sale of 1,500 shares (~$200K) under a pre-arranged 10b5-1 plan is generally treated as routine and not a strong standalone fundamental catalyst.

02

Market read

Traders may note the disclosure for sentiment/positioning, but the 10b5-1 framing suggests limited incremental information.

03

What to watch

The article provides only the sale size and that it was pre-arranged; it does not indicate whether other insiders or large holders are buying, nor any concurrent fundamental catalysts.

Relevance 3/10Novelty 6/10Timing: SEC Form 4 filed 2026-06-16 for a sale dated 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for StoneX Group Inc. (SNEX).

Company-level read

Ticker impact

$SNEXNeutralHigh confidence
Context

StoneX Group Inc. insider director BEXIGA ANNABELLE G sold 1,500 shares in an open-market transaction for about $200K under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale; any impact would be sentiment-driven and short-lived.

Evidence & confidence

The filing is an SEC Form 4 insider sale with explicit 10b5-1 pre-arrangement, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector-level read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with management’s view of near-term risk or valuation, so traders may watch for follow-on selling patterns.

Key entities

  • StoneX Group Inc.

    Company whose director insider sale is disclosed on SEC Form 4.

  • BEXIGA ANNABELLE G

    Director who sold 1,500 shares on 2026-06-15 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$WGOMedAI 8/10

Winnebago stock rises as StoneX lowers price target on industry outlook

StoneX lowered its price target on Winnebago (WGO) to $36 from $40, maintaining a Buy rating. The stock trades at $26.83 with a 5.62% dividend yield. Winnebago issued fiscal 2027 guidance for sales of $2.65B-$2.80B and adjusted EPS of $1.65-$2.25, with midpoints above consensus. The company reduced 2026 RV shipment expectations and guided 2027 shipments to 265,000-295,000 units. The stock rose 10.5% on Monday following earnings and guidance.

$MXLMed

MaxLinear stock rating reiterated at Buy by StoneX ahead of results

StoneX reiterated a Buy rating on MaxLinear (MXL) with a $125 price target ahead of its October 22 earnings report. The firm expects Q3 revenue of $215M-$220M, matching consensus. MXL shares are down 20% in a week but up 320% year-to-date. S&P upgraded its outlook to positive, citing strong infrastructure revenue growth. Analysts highlight MXL's potential in the optical market.

$EQBKMed

StoneX lowers Equity Bancshares stock price target on NIM outlook

StoneX reduced its price target for Equity Bancshares (EQBK) to $58 from $59, citing net interest margin expectations. The firm raised its fiscal 2026 EPS forecast to $5.18 but lowered the 2027 estimate to $5.27. EQBK's stock trades at a P/E ratio of 10.58, and analysts expect net income growth. The company recently reported Q3 earnings beating estimates, with EPS of $1.40 vs. $1.29 expected, but revenue missed slightly.